Cardiac AI Cloud Platform Revolutionizes Cardiac Care with Innovative Partnerships and Market Expansion

Santa Clara, California – Biotricity, a healthcare technology company based in Santa Clara, California, recently held its Q4 2024 Earnings Conference Call on June 27, 2024, at 4:30 PM ET. The call provided insight into the company’s financial results and business updates for the fiscal year. Key participants in the call included Waqaas Al-Siddiq, the Founder and CEO of Biotricity, and John Ayanoglou, the CFO.

During the call, Al-Siddiq highlighted the company’s significant progress in fiscal year 2024, emphasizing advancements in revenue growth, improved margins, and reduced EBITDA losses. One of the major achievements mentioned was the expansion of Biotricity’s Cardiac AI Cloud platform through strategic partnerships with industry leaders like Amazon AWS and Google’s TensorFlow. This initiative aims to enhance diagnostic accuracy, improve patient outcomes, and increase clinic profitability.

The company also announced strategic alliances with three top group purchasing organizations (GPOs), expanding its market reach to approximately 90% of hospitals in the U.S. This partnership is expected to strengthen Biotricity’s presence in the healthcare technology sector and provide access to a wide range of market channels.

Additionally, Biotricity received Health Canada approval for its Biocore device, paving the way for revenue growth in the Canadian cardiology devices market. The company also launched the Biocore Pro, a next-generation cardiac monitoring device, and entered into key partnerships to provide heart health screenings at high-profile events. These initiatives demonstrate Biotricity’s commitment to expanding its market footprint and delivering innovative solutions in the healthcare industry.

Looking ahead, Biotricity aims to accelerate its path to breakeven by capitalizing on the rapid adoption of its Biocore Pro device and expanding into the pulmonary and neurology fields through partnerships with leading home-based diagnostic companies. The company also launched HeartSecure, a direct-to-consumer heart health screening service, targeting the home heart health market and addressing the global challenge of cardiovascular disease.

Overall, Biotricity’s strategic initiatives, technological advancements, and operational efficiencies have positioned the company for sustained growth and profitability. With a focus on delivering innovative cardiac care solutions and improving patient outcomes, Biotricity remains confident in its ability to drive value for shareholders and make a positive impact in the healthcare industry.